Why do I treat my patients with mild hepatitis C? by Calvaruso V & Crax&#236
REVIEW ARTICLE
Why do I treat my patients with mild hepatitis C?
Vincenza Calvaruso and Antonio Craxı
Sezione di Gastroenterologia & Epatologia, DIBIMIS, Universita di Palermo, Palermo, Italy
DOI: 10.1111/liv.13011
Abstract
The major advances achieved in the treatment of HCV by the development of new direct-acting antiviral agents (DAAs)
allow treatment of almost the entire spectrum of patients with chornic infection. As a result of the exceedingly high cost of
DAAs in many countries, IFN-free DAA regimens are mostly reserved to patients with advanced fibrosis or cirrhosis. Hence,
treatment of patients with milder liver disease is often deferred. This could ultimately result in an increased burden of
advanced liver disease and in increased long-term costs of management. Moreover, studies performed during the ‘interferon
era’ and the early data on interferon-free regimens show that patients without severe fibrosis achieve higher rates of sus-
tained virological response with less treatment-related adverse events. Unfortunately, there is no univocal way to predict the
progression of liver fibrosis and therefore to identify the patients with early disease who would require urgent HCV treat-
ment. Many studies have also demonstrated that treatment-induced HCV clearance reduces all-cause mortality regardless of
the stage of liver fibrosis, pointing to an effect on extrahepatic manifestations of HCV infection. Last but not least, pharma-
coeconomic studies show that DAA treatment of patients with mild HCV disease is cost-effective even at high prices of
drugs, thus suggesting the opprtunity to treat regardless of the stage of liver disease.
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Chronic hepatitis C may eventually progress to cirrho-
sis, liver decompensation and hepatocellular carcinoma
and many studies proved that HCV eradications reduce
the risk of developing liver complications (1). Moreover
one multicenter international study has already demon-
strated that achieving SVR reduces not only liver related
but also all-cause and non-liver-related mortality (2).
The availability of new direct-acting antiviral agents
(DAAs) have changed the scenario of HCV treatment
but the high costs of these regimens caused relevant
restrictions of access to the drugs. Patients with early
fibrosis stages will not have access to the new therapies
and this will increase the risk to development of severe
liver fibrosis, of hepatocellular carcinoma and liver
decompensation.
When we delay the antiviral treatment in patients
with chronic HCV-related mild hepatitis we need to tak-
ing into account the following issues (Fig. 1):
• Unpredictable course of liver disease at individual
level (influence of cofactors)
• Patients with mild fibrosis are ‘easy to treat’
• HCV eradications as cure of extrahepatic complica-
tions
• Pharmacoeconomic considerations
Unpredictable course of liver disease at individual
level (influence of cofactors)
In the last years, a lot of studies have tried to identify
patients at early disease stages but high risk of fibrosis
progression. Indeed, recognizing the cofactors that con-
tribute to disease progression among HCV patients may
ameliorate treatment approaches and overall disease
management. Many studies have focused on the impact
of obesity and metabolic disorders on the natural his-
tory of chronic HCV and as is already known, the effects
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of diabetes mellitus, metabolic syndrome and nonalco-
holic fatty liver disease (NAFLD) have been related to
the progression of hepatic fibrosis (3). However, the
impact of the those factors on progression of disease
among chronic HCV patients is still controversial
because of conflicting results of existing studies (4, 5).
Data from literature have shown that oestrogens exert
a beneficial effect on liver disease by slowing the pro-
gression of fibrosis (6) and Villa et al. (7) have recently
demonstrated that the progression of fibrosis in women
is a discontinuous process: very slow during reproduc-
tive age and rapid after menopause. The authors have
found that the severity of liver necroinflammation and
fibrosis, was very low in women of reproductive age and
in premenopausal ones while it increase among early
menopausal women and became very higher among late
menopausal women. Furthermore, the levels of circulat-
ing estradiol was found independently related with sev-
ere fibrosis.
In another study (8), the same group have also found
that the more pronounced inflammatory state associate
to the more rapid progression to fibrosis resulted in an
higher resistance to antiviral therapy. This suggests that
CHC in women should be treated early, regardless the
fact that they have mild liver disease, as this condition
will last only as long as the oestrogen-exposed period
and the progression to a severe liver fibrosis remains not
predictable.
Both European and US guidelines reccomend (9, 10)
to prioritize the treatment of patients with HIV or HBV
coinfection regardless of the fibrosis stage.
Indeed, whereas treatment of HIV with ART appears
to slow the progression of liver disease, coinfected
patients remain at greater risk for HCV disease progres-
sion than patients with HCV monoinfection (11). In the
era of several new DAA combination therapies, treat-
ment response rates no longer differ between HIV/
HCV-coinfected and HCV-monoinfected patients;
Therefore, in countries with access to the new DAAs,
interferon-free DAA-containing treatment is strongly
recommended for those patients and the antiviral regi-
men should be selected based on HCV genotype and
according to current guidelines as drug–drug interac-
tions between cART, ribavirin, and especially the new
HCV protease inhibitors. A careful selection of both
HIV and HCV drugs is required as well as close moni-
toring. Also in patients with HBV coinfection the HCV
antiviral treatment should be performed with the same
rules as applied to HCV-monoinfected patients. How-
ever, there is a potential risk of HBV reactivation during
or after HCV clearance (12) and if HBV replication is
detectable at a significant level, HBV nucleoside/nu-
cleotide analogue therapy is indicated. Potential drug–
drug interaction have been shown between simeprevir
and tenofovir. Therefore, in patients receiving tenofovir
as anti-HBV treatment, the eGFR and tubular function
should be monitored frequently during treatment and
tenofovir dose adjustment may be necessary.
Recent genome-wide association studies (GWAS)
have highlighted several genetic polymorphisms as pre-
dictive risk factors of rapid fibrosis progression in
chronic hepatitis C (13–15). Interleukin 28B (IL28B)
genotype may be associated with fibrosis progression
after interferon-based therapy, although the results of
recent studies remained inconclusive (13). More
recently, a series of SNPs [MERTK (rs4374383), TULP1
(rs9380516), GLT8D2 (rs2629751) and RNF7
(rs16851720)] have been identified as susceptible genetic
alterations for HCV-related liver fibrosis (16), and other
studies have proposed SNPs at rs738409 in adiponutrin/
patatin-like phospholipase domain-containing 3
(PLPNA3) as genetic determinants of liver fat content,
disease progression and fibrosis in nonalcoholic fatty
liver disease (NAFLD) and in chronic hepatitis C (17–
19). However, most of these results require verification,
HCV eradicaon in paents with 
mild hepas
Easy to treat
Avoid the unpredictable
progression of liver ﬁbrosis
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Fig. 1. Main indications of HCV antiviral therapy in patients with
mild liver disease.
Key points
 The impact of clinical, metabolic and genetic fac-
tors which are associated with liver fibrosis in
chronic HCV patients is still controversial, and the
progression of disease remains largely unpre-
dictable.
 The majority of patients with immunological dri-
ven extrahepatic complications as Mixed cryo-
globulinemia and Non-Hodgkin Lymphoma had
complete resolution with successful HCV clear-
ance.
 Viral eradication is able to reduce the risk of car-
diovascular and metabolic disease and also of
non-liver related mortality.
 Pharmacoeconomic analysis confirmed that IFN-
free regimens are more cost-effective that IFN-
based therapy for all HCV patients.
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and whether the combined use of these genetic predic-
tors can assess the risk of fibrosis progression in patients
with HCV after antiviral therapy remains unclear.
Easy to treat
The severity of liver disease with extensive fibrosis
or cirrhosis, was identified as important additional
determinants of the SVR in IFN-a/ribavirin-based
regimens (20, 21).
Even if the new antiviral drugs are much less
influenced by host or viral parameters and achieve
higher cure rates also in patients with severe fibrosis,
overall, severe disease is associated with lower SVR
rates on both IFN-containing and IFN-free combination
regimens (22, 23).
In Neutrino study (22), more than three hundreds
patients with HCV genotype 1, 4, 5, or 6, were treated
with sofosbuvir combined with peg-interferon and rib-
avirin. The variables associated with therapy response
were cirrhosis, IL28B (rs12979860) genotype and rib-
avirin exposure. The SVR12 for patients with genotype
1 infection was 89.4%, but the SVR12 was inferior in
patients with cirrhosis (80%) than in those without cir-
rhosis (92%). Also in the cohort of 499 patients with
HCV genotype 2 or 3 received sofosbuvir and ribavirin,
the predictive factors associated with SVR12 were HCV
genotype, presence of cirrhosis, HCV-RNA viral load at
baseline and ribavirin exposure. The response rates were
lower among patients with cirrhosis than for those with-
out cirrhosis (46.9% vs 72.1%).
This is due to a slower second-phase HCV-RNA
decline in cirrhotic than in non-cirrhotic patients. The
molecular mechanisms underlying the slower infected
cell clearance in cirrhotic patients are unknown. It does
not appear to be related to different drug exposures in
cirrhotics because the first-phase response is identical in
cirrhotic and non-cirrhotic patients. Differences in the
cirrhotic liver microenvironment might be responsible
for differences in the mechanisms of HCV clearance
activated in infected cells on efficient antiviral therapy.
Treatment duration is a key parameter that can be easily
optimized to increase the SVR rates. Stopping treatment
too early, before the last infected cell has been cleared or
cured, results in reinfection of liver cells, and ultimately,
in a virological relapse. In contrast, stopping therapy at
any time after the last cell has been eliminated is associ-
ated with a definitive cure of infection. Thus, patients
with a slow second-phase decline, such as patients with
an unfavourable IL28B genotype, cirrhotics, patients
infected with HCV genotype 3, etc., need longer therapy
than those with a sharp one, regardless of the treatment
regimen.
In patients with cirrhosis the use of ribavirin in
reccomended. Indeed, Ribavirin accelerates the sec-
ond-slope of viral decline in a dose-dependent man-
ner in patients in whom virus production is
efficiently blocked by IFN-containing or IFN-free
drug combinations, through mechanisms that remain
debated (24). Thus, ribavirin remains a useful tool to
either reduce treatment duration or improve SVR
rates and because it is cheap and relatively well toler-
ated when it is not combined with IFN-a, it remains
a very useful tool to anti-HCV treatment regimens
and optimize their results. However, the use of rib-
avirin remains especially challenging in patients with
anaemia and concomitant renal impairment and adds
both side effects and the need for monitoring to any
regimen. Therefore, patients with previous evidence
of intolerance to ribavirine should be treated before
the development of severe fibrosis to avoid the risk
to receive a suboptimal antiviral regimen.
All these considerations clearly suggest that the effi-
cacy of antiviral treatment in patients without mild
fibrosis can result higher and that regimens could be
shorter with a consequentially reduction in side effects
and costs.
Extrahepatic complications
The liver is not the unique organ affected by chronic
hepatitis C infection. Indeed, a broad clinical spectrum
of extrahepatic complications are associated with this
viral infection (25).
In the majority of these associated extrahepatic
manifestations, the pathogenic mechanism appears to
be immunologically driven, HCV lymphotropism rep-
resents the most relevant step in the pathogenesis of
virus-related immunological disorders (26). Indeed,
infected lymphoid tissue of the host represents a site
for the persistence of the HCV infection. HCV exerts
a chronic stimulus to the immune system, facilitating
the clonal B-lymphocyte expansion and consequent
wide autoantibody production, including cryo- and
non-cryoprecipitable immune complexes which may
lead to organ and non-organ-specific immunological
alterations (27).
Mixed cryoglobulinemia (MC) is the most well docu-
mented extrahepatic manifestation of HCV infection
(26). About 40–60% of HCV-infected patients have cir-
culating cryoglobulins even if only 5–10% of these indi-
viduals develop clinical consequences (28). Cutaneous
vasculitis with palpable purpura, occurs in one-third of
patients ranging from asymptomatic pigmentation to
cutaneous ulceration. Renal disease with membranopro-
liferative glomerulonephritis (GN) occurs in about 30%
of patients, ranging from mild proteinuria to progres-
sive renal impairment. Other less frequent symptoms
are neuropathy (11–30%), sicca syndrome (10–25%)
and arthralgias (35–54%) (29, 30).
This is the reason why in these patients the inter-
feron-based antiviral treatment has been often pro-
posed. The benefit of antiviral treatment on MC related
complications had been demostrated with the introduc-
tion of peginterferon and ribavirin. With this combina-
tions the rates of SVR increased and follow-up studies
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showed that 80–90% of patients had complete resolution
of sympthoms with successful viral eradication (31).
However, because of its immune-stimulatory effects,
interferon may exacerbate some of the symptoms of MC
vasculitis, limiting the tolerability of therapy. Thus, the
introduction of interferon-free DAA regimens holds
great promise for treating HCV-associated MC.
Similar to MC, even low-grade Non-Hodgkin Lym-
phoma may respond to antiviral therapy. NHL remission
has been reported in a small number of patients treated
with interferon-free DAA-based regimens, suggesting
that the effect is all virally mediated and not because of
anti-proliferative effects of interferon (32). In a Japanese
study, HCV therapy seems also able been to reduce the
incidence of new onset NHL, making a case for consider-
ation of earlier treatment, even in patients with mild liver
disease to prevent future complications (33).
Also in patients with high-grade NHL where a pri-
mary treatment of the malignancy is required, the
achievement of SVR markedly reduces the risk of
NHL relapse (34). suggesting that therapy with DAAs
could be given with or even before chemotherapy for
high-grade NHL, to improve responses without affect
tolerability.
According with these data, patients with evidence of
MC, even if with mild liver disease, may represent a
population who should be prioritized for early antiviral
therapy to prevent future symptomatic vasculitis and
lymphoma (30).
In the last years, a lot of studies have shown a higher
incidence of cardiovascular and metabolic disorder in
patients with chronic HCV infection.
A correlation between HCV infection and
atherosclerotic changes has been recently proved and
the risk of peripheral artery disease is higher than in
uninfected patients (35, 36). Those results suggest that
the risk of cardiovascular events and mortality may be
elevated among HCV-infected patients and become rel-
evant to assess if eradication of HCV may reduce the
risk of cardiovascular disease. A large, retrospective
cohort study found that interferon-based therapy sig-
nificantly reduced stroke incidence compared with no
treatment (37). and the long-term extrahepatic benefits
of successfully treating HCV infection has been
demonstrated also in another recent study where
patients with HCV infection treated with interferon-
based treatment significantly reduced the incidence of
end-stage renal disease, acute coronary syndrome and
ischaemic stroke (38).
Data from the literature have shown a higher inci-
dence of type 2 diabetes mellitus with chronic HCV
when compared with patients with other liver disorders
(25, 39).
Moreover, type 2 diabetic HCV patients had a signifi-
cantly lower BMI than type 2 diabetic control subjects
and significantly higher BMI than non-diabetic HCV
patients. In contrast, no association with diabetes melli-
tus type 1 has been identified (39, 40).
The association between chronic HCV and diabetes
mellitus seems to be independent of the severity of the
liver disease and is associated with insulin resistance
(30, 41).
Insulin resistance correlates with poor outcomes in
HCV patients, including accelerated progression of hep-
atic fibrosis, reduced SVR rates, development of HCC
and of type 2 diabetes and its cardiovascular sequelae.
Kawaguchi et al. (42), demonstrated that curing
HCV with antiviral therapy results in reduced levels of
insulin resistance, while levels remain unchanged in
virological non-responders. Furthermore a study of an
interferon-free, short course of an inhibitor of the HCV
non-structural 3 (NS3) serine protease, showed a close
correlation between viral load decline and reduction in
HOMA-IR levels (43), suggestig that treatment with
anti-HCV DAAs may restore insulin sensitivity in
chronic HCV-infected patients.
All these evidences confirm that the involvement of
non-hepatic organ systems in HCV infection substan-
tially decreases the quality of life of chronically infected
patients, and may also increase non-hepatic mortality.
Viral eradication reduces extrahepatic manifestations of
HCV, and these new regimens which are also better tol-
erated result strongly indicated for those patients. Not
surprisingly, major clinical practice guidelines of inter-
national societies have already defined the presence of
extrahepatic manifestations as a priority indication for
antiviral treatment with DAAs, even in the absence of
liver disease (9).
Cost-effect analysis
The global prevalence of hepatitis C virus (HCV) infec-
tion, the rate of progression of chronic disease to cirrho-
sis and liver events and the rapid changing scenario of
HCV terapy have lead many groups to perform cost-
effect analysis to assess the best strategy of treatment in
this setting.
The first study which evaluated the cost effect of
Sofosbuvir combined with peg-interferon and ribavirin
compared with triple therapy with Bocepevir or
Telaprevir, concluded that SOF was cost-effective com-
pared with BOC in all strategies and thus also in patients
with mild fibrosis, however, in comparison with TVR-
based strategies, SOF was cost-effective in IL28B CT/TT
and G1a patients, and not cost-effective in patients with
mild or severe fibrosis and in G1b patients (44).
However in a more recent study, Younossi et al. (45)
compared IFN-free regimens with IFN-based triple ther-
apy and they found that the IFN-free regimens is supe-
rior of IFN-based therapy for all G1-HCV patients.
Furthermore, they concluded that staging fibrosis in
CHC is not cost-effective. Indeed IFN free without stag-
ing was more cost-effective than oral IFN-free regimen
after staging. This study suggests for the first time that
with the achievement of high SVR rates by highly effec-
tive IFN-free regimens which caused low side effects and
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that can be administered for shorter duration, the deci-
sion to treat or not to treat should not be based on the
stage of liver disease.
Similarly, another study have evaluated the cost-
effective analysis of sofosbuvir and ledipasvir (46). The
authors concluded that treatment not only reduce
HCV-related complications but it is cost-effective in the
majority of patients.
However, in the conclusion, the authors discuss with
major concerns about the possibility to find the
immense economic budget to cover the costs of treat-
ment for all HCV treatment-eligible.
Conclusions
In the era of IFN-free regimen with high efficacy rates
and better safety profile, treating all HCV patients with
IFN-free oral therapy appears to improve outcomes and
be more cost-effective. In this review we have analysed
the many reasons why we should treat also patients
without significant liver damage. Antiviral therapy in
patients with mild disease is easier as regimens could be
shorter and without combination with ribavirin; HCV
eradications significantly reduce the progression of liver
fibrosis and acts as cure for the extrahepatic manifesta-
tions. Another particular condition in which treatment
should be prioritized regardless of the fibrosis stage is
the patients who have an high risk of transmitting HCV
as active injection drug users, men who have sex with
men with high-risk sexual practices, incarcerated per-
sons, persons on long-term haemodialysis, HCV-
infected women wishing to get pregnant and healthcare
workers who perform invasive procedures. This analysis
suggests that liver disease stage-guided treatment proto-
cols should be revisited and that additional resources as
well as patient prioritization are needed to manage HCV
patients.
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